188 related articles for article (PubMed ID: 25960322)
1. Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
Hamaguchi W; Masuda N; Miyamoto S; Kikuchi S; Narazaki F; Shiina Y; Seo R; Amano Y; Mihara T; Moriguchi H; Hattori K
Bioorg Med Chem; 2015 Jul; 23(13):3351-67. PubMed ID: 25960322
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition.
Hamaguchi W; Masuda N; Miyamoto S; Shiina Y; Kikuchi S; Mihara T; Moriguchi H; Fushiki H; Murakami Y; Amano Y; Honbou K; Hattori K
Bioorg Med Chem; 2015 Jan; 23(2):297-313. PubMed ID: 25515954
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
6. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors.
Hamaguchi W; Masuda N; Samizu K; Mihara T; Takama K; Watanabe T
Chem Pharm Bull (Tokyo); 2014; 62(12):1200-13. PubMed ID: 25450629
[TBL] [Abstract][Full Text] [Related]
8. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
9. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
[TBL] [Abstract][Full Text] [Related]
12. Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).
Hu E; Chen N; Bourbeau MP; Harrington PE; Biswas K; Kunz RK; Andrews KL; Chmait S; Zhao X; Davis C; Ma J; Shi J; Lester-Zeiner D; Danao J; Able J; Cueva M; Talreja S; Kornecook T; Chen H; Porter A; Hungate R; Treanor J; Allen JR
J Med Chem; 2014 Aug; 57(15):6632-41. PubMed ID: 25062128
[TBL] [Abstract][Full Text] [Related]
13. N-Acylhydrazones as inhibitors of PDE10A.
Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
[TBL] [Abstract][Full Text] [Related]
15. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.
Hu E; Kunz RK; Rumfelt S; Chen N; Bürli R; Li C; Andrews KL; Zhang J; Chmait S; Kogan J; Lindstrom M; Hitchcock SA; Treanor J
Bioorg Med Chem Lett; 2012 Mar; 22(6):2262-5. PubMed ID: 22365755
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: part II.
Das S; Shelke DE; Harde RL; Avhad VB; Khairatkar-Joshi N; Gullapalli S; Gupta PK; Gandhi MN; Bhateja DK; Bajpai M; Joshi AA; Marathe MY; Gudi GS; Jadhav SB; Mahat MY; Thomas A
Bioorg Med Chem Lett; 2014 Aug; 24(15):3238-42. PubMed ID: 24980052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]